BioCentury
ARTICLE | Company News

Selvita, Menarini deal

March 31, 2017 7:44 PM UTC

Selvita granted Menarini exclusive, worldwide rights to develop and commercialize acute myelogenous leukemia (AML) candidate SEL24. Selvita will receive an upfront payment of €4.8 million ($5.2 millio...